HMGB1 and melanoma: Results from studies carried out to better understand the RB mechanism of action and its role in managing melanoma showed that intralesional RB injection induced a tumor-specific T-cell-mediated immune response [15] through activation of dendritic cells and release of high-mobility group box 1 to enhance a systemic immune response against melanoma [16].